L
Lara Aprile
Researcher at University of Siena
Publications - 27
Citations - 241
Lara Aprile is an academic researcher from University of Siena. The author has contributed to research in topics: Myeloid leukemia & Nilotinib. The author has an hindex of 7, co-authored 23 publications receiving 174 citations.
Papers
More filters
Journal ArticleDOI
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia,Anna Sicuranza,Elisabetta Abruzzese,Alessandra Iurlo,Santina Sirianni,Antonella Gozzini,Sara Galimberti,Lara Aprile,Bruno Martino,Patrizia Pregno,Federica Sorà,Giulia Alunni,Carmen Fava,Fausto Castagnetti,Luca Puccetti,Massimo Breccia,Daniele Cattaneo,Marzia Defina,Olga Mulas,Claudia Baratè,Giovanni Caocci,Simona Sica,Alessandro Gozzetti,Luigiana Luciano,Monica Crugnola,Mario Annunziata,Mario Tiribelli,Paola Pacelli,Ilaria Ferrigno,Emilio Usala,Nicola Sgherza,Gianantonio Rosti,Alberto Bosi,Donatella Raspadori +33 more
TL;DR: This cross-sectional study provides the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation.
Journal ArticleDOI
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study
Anna Candoni,Davide Lazzarotto,Felicetto Ferrara,Antonio Curti,Federico Lussana,Cristina Papayannidis,Maria Ilaria Del Principe,Massimiliano Bonifacio,Federico Mosna,Mario Delia,Paola Minetto,Michele Gottardi,Nicola Stefano Fracchiolla,Valentina Mancini,Fabio Forghieri,Patrizia Zappasodi,Marco Cerrano,Antonella Vitale,Ernesta Audisio,Silvia Trappolini,Claudio Romani,Marzia Defina,Silvia Imbergamo,Nadia Ciccone,Lidia Santoro,Benedetta Cambò,Salvatore Iaccarino,Michela Dargenio,Lara Aprile,Sabina Chiaretti,Renato Fanin,Giovanni Pizzolo,Roberto Foa +32 more
TL;DR: Taking into account the poor prognosis of this patient population, nelarabine represents an effective option with an ORR of 50% and a CR rate of 36% and in addition, 40% of cases following nelARabine salvage therapy could undergo SCT with an expected OS at 2 and 5 years of 46% and 38%, respectively.
Journal ArticleDOI
Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
Monica Bocchia,Marzia Defina,Lara Aprile,Micaela Ippoliti,Rosaria Crupi,Michela Rondoni,Alessandro Gozzetti,Francesco Lauria +7 more
TL;DR: A 63-year-old woman with chronic myeloid leukemia with chronic-phase, Philadelphia-positive CML that was still detectable after complete cytogenic response 2 years after cessation of IFN-α therapy is in complete molecular response with an undetectable level of BCR–ABL1 transcript both in peripheral blood and in bone marrow.
Journal ArticleDOI
Genetic predisposition and induced pro-inflammatory/pro- oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients
Monica Bocchia,Sara Galimberti,Lara Aprile,Anna Sicuranza,Antonella Gozzini,Francesca Santilli,Elisabetta Abruzzese,Claudia Baratè,Barbara Scappini,Giulia Fontanelli,M. M. Trawinska,Marzia Defina,Alessandro Gozzetti,Alberto Bosi,Mario Petrini,Luca Puccetti +15 more
TL;DR: It is believed that in nilotinib patients an induced “inflammatory/oxidative status”, together with a genetic pro-atherothrombotic predisposition, may favour the increased incidence of CV events.
Journal ArticleDOI
Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy
Marzia Defina,Micaela Ippoliti,Alessandro Gozzetti,Elisabetta Abruzzese,Fausto Castagnetti,Rosaria Crupi,Mario Tiribelli,Massimo Breccia,Marzia Salvucci,Lara Aprile,Claudia Baratè,Antonella Gozzini,Gianantonio Rosti,Francesco Lauria,Monica Bocchia +14 more
TL;DR: Nilotinib is a potent breakpoint cluster region/v‐abl Abelson murine leukemia viral oncogene (bcr‐abl) kinase inhibitor, and it induces higher rate and rapid complete cytogenetic response (CCyR), yet no clinical data are available regarding its efficacy against chronic myeloid leukemia (CML) stem cells.